Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2015

Open Access 01-12-2015 | Research article

Metaplastic breast cancer: a comparison between the most common histologies with poor immunohistochemistry factors

Authors: Salim Abraham Barquet-Muñoz, Silvia Patricia Villarreal-Colin, Luis Alonso Herrera-Montalvo, Ernesto Soto-Reyes, Carlos Pérez-Plasencia, Jaime Coronel-Martínez, Delia Pérez-Montiel, Rafael Vázquez-Romo, David Cantú de León

Published in: BMC Cancer | Issue 1/2015

Login to get access

Abstract

Background

Metaplastic carcinoma of the breast (MCB) is a rare histological type of breast cancer. This study aimed to determine whether MCB exhibits shorter overall survival (OS) and disease-free survival (DFS) compared with other histologies that are considered unfavorable.

Methods

We retrospectively analyzed 157 clinical file records of the Mexico City-based National Institute of Cancerology and compared the clinical characteristics and treatment of 24 patients with MCB, 37 patients with triple-negative invasive lobular carcinoma (TN-ILC), 48 patients with high-grade invasive ductal carcinoma (HG-IDC), and 48 patients with triple-negative invasive ductal carcinoma (TN-IDC), paired by clinical stage and age. We performed a comparative analysis and analyzed OS and DFS using a log-rank test.

Results

In patients with MCB, the 5-year DFS was 52.1% (mean, 48.52 months; 95%: 35.32-61.72), and the 5-year OS was 72.2% (mean, 59.77 months; 95% CI: 48.55-71.00). No differences were observed in the DFS of MCB compared with each of the other histologies (MCB vs. HG-IDC, p = 0.865; MCB vs. TN-IDC, p = 0.966, and MCB vs. TN-ILC, p = 0.132). Moreover, no differences were observed when comparing the OS of MCB with that of each of the other histologies (MCB vs. HG-IDC, p = 0.246; MCB vs. TN-IDC, p = 0.255, and MCB vs. TN-ILC, p = 0.387).

Conclusions

Neither OS nor DFS differ between patients with MCB and those with other histologies with unfavorable immunohistochemical factors.
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2012): GLOBOCAN 2012 v1. 0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer. http://​globocan.​iarc.​fr.
2.
Villarreal-Garza C, Aguila C, Magallanes-Hoyos MC, Mohar A, Bargalló E, Meneses A, et al. Breast cancer in young women in Latin America: an unmet, growing burden. Oncologist. 2013;18:1298–306.CrossRefPubMedPubMedCentral
3.
Harvey JA. Unusual breast cancers: useful clues to expanding the differential diagnosis. Radiology. 2007;242:683–894.CrossRefPubMed
4.
Catroppo JF, Lara JF. Metastatic metaplastic carcinoma of the breast (MCB): an uncharacteristic pattern of presentation with clinicopathologic correlation. Diagn Cytopathol. 2001;25:285–91.CrossRefPubMed
5.
Beatty JD, Atwood M, Tickman R, Reiner M. Metaplastic breast cancer: clinical significance. Am J Surg. 2006;191:657–64.CrossRefPubMed
6.
Tse GM, Tan PH, Putti TC, Lui PC, Chaiwun B, Law BK. Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol. 2006;59:1079–83.CrossRefPubMedPubMedCentral
7.
Pezzi CM, Patel-Parekh L, Cole K, Franko J, Klimberg VS, Bland K. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National cancer data Base. Ann Surg Oncol. 2007;14:166–73.CrossRefPubMed
8.
Gibson GR, Qian D, Ku JK, Lai LL. Metaplastic breast cancer: clinical features and outcomes. Am Surg. 2005;71:725–30.PubMed
9.
Tseng WH, Martínez SR. Metaplastic breast cancer: to radiate or not to radiate? Ann Surg Oncol. 2011;18:94–103.CrossRefPubMed
10.
Yamaguchi R, Horii R, Maeda I, Suga S, Makita M, Iwase T, et al. Clinicopathologic study of 53 metaplastic breast carcinomas: their elements and prognostic implications. Hum Pathol. 2010;41:679–85.CrossRefPubMed
11.
Park JM, Han BK, Moon WK, Choe YH, Ahn SH, Gong G. Metaplastic carcinoma of the breast: mammographic and sonographic findings. J Clin Ultrasound. 2000;28:179–86.CrossRefPubMed
12.
Luini A, Aguilar M, Gatti G, Fasani R, Botteri E, Brito JA, et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 2007;101:349–53.CrossRefPubMed
13.
Dave G, Cosmatos H, Do T, Lodin K, Varshney D. Metaplastic carcinoma of the breast: a retrospective review. Int J Radiat Oncol Biol Phys. 2006;64:771–5.CrossRefPubMed
14.
Tavassoli FA, Devilee P. The WHO Classification of Tumors. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon, France: IARC Press; 2003.
15.
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. Hum Pathol. 1989;20:628–35.CrossRefPubMed
16.
Wargotz ES, Deos PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. Hum Pathol. 1989;20:732–40.CrossRefPubMed
17.
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast III. Carcinosarcoma. Cancer. 1989;64:1490–9.CrossRefPubMed
18.
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast IV Squamous cell carcinoma of ductal origin. Cancer. 1990;65:272–6.CrossRefPubMed
19.
Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast: V. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol. 1990;21:1142–50.CrossRefPubMed
20.
21.
Gilbert JA, Goetz MP, Reynolds CA, Ingle JN, Giordano KF, Suman VJ, et al. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Mol Cancer Ther. 2008;7:944–51.CrossRefPubMedPubMedCentral
22.
Jung SY, Kim HY, Nam BH, Min SY, Lee SJ, Park C, et al. Worse prognosis of metaplastic breast cancer patients than other patients with triple-negative breast cancer. Breast Cancer Res Treat. 2010;120:627–37.CrossRefPubMed
23.
Vela-Chávez TA, Ruvalcaba-Limón E, Pérez-Sánchez VM. EGFR analysis in metaplastic carcinoma of the breast [Abstract]. Eur J Cancer. 2008;6:86.
24.
Al Sayed AD, El Weshi AN, Tulbah AM, Rahal MM, Ezzat AA. Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors. Acta Oncol. 2006;45:188–95.CrossRefPubMed
25.
Montagna E, Maisonneuve P, Rotmensz N, Cancello G, Iorfida M, Balduzzi A, et al. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer. 2013;13:31–9.CrossRefPubMed
26.
Lee H, Jung SY, Ro JY, Kwon Y, Sohn JH, Park IH, et al. Metaplastic breast cancer: clinicopathological features and its prognosis. J Clin Pathol. 2012;65:441–6.CrossRefPubMed
27.
Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, et al. Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013;11:753–60.PubMedPubMedCentral
28.
Lu Y-S, Huang C-S, Cheng A-L. Poor response to systemic chemotherapy in metaplastic carcinoma of breast. EJC Suppl. 2009;7:289.
29.
Chao TC, Wang CS, Chen SC, Chen MF. Metaplastic carcinomas of the breast. J Surg Oncol. 1999;71:220–5.CrossRefPubMed
30.
Rayson D, Adjei AA, Suman VJ, Wold LE, Ingle JN. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol. 1999;10:413–9.CrossRefPubMed
31.
Lai HW, Tseng LM, Chang TW, Kuo YL, Hsieh CM, Chen ST, et al. The prognostic significance of metaplastic carcinoma of the breast (MCB)–a case controlled comparison study with infiltrating ductal carcinoma. Breast. 2013;22:968–73.CrossRefPubMed
32.
Song Y, Liu X, Zhang G, Song H, Ren Y, He X, et al. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators. World J Surg Oncol. 2013;11:129.CrossRefPubMedPubMedCentral
33.
Bae SY, Lee SK, Koo MY, Hur SM, Choi MY, Cho DH, et al. The prognoses of metaplastic breast cancer patients compared to those of triple-negative breast cancer patients. Breast Cancer Res Treat. 2011;126:471–8.CrossRefPubMed
34.
Park HS, Park S, Kim JH, Lee JH, Choi SY, Park BW, et al. Clinicopathologic features and outcomes of metaplastic breast carcinoma: comparison with invasive ductal carcinoma of the breast. Yonsei Med J. 2010;51:864–9.CrossRefPubMedPubMedCentral
35.
Mourad WA. Book review: Rosen’s breast pathology. Ann Saudi Med. 1998;18:278.PubMed
36.
Weigelta B, Geyerb FC, Reis-Filhob JS. Histological types of breast cancer: how special are they? Mol Oncol. 2010;4:192–208.CrossRef
37.
Chen IC, Lin CH, Huang CS, Lien HC, Hsu C, Kuo WH, et al. Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. Breast Cancer Res Treat. 2011;130:345–51.CrossRefPubMed
38.
Nelson RA, Guye ML, Luu T, Lai LL: Survival outcomes of metaplastic breast cancer patients: results from a US population-based analysis. Ann Surg Oncol 2014. [Epub ahead of print]. doi: 10.1245/s10434-014-3890-4
39.
Paul Wright G, Davis AT, Koehler TJ, Melnik MK, Chung MH. Hormone receptor status does not affect prognosis in metaplastic breast cancer: a population-based analysis with comparison to infiltrating ductal and lobular carcinomas. Ann Surg Oncol. 2014;21:3497–503.CrossRefPubMed
Metadata
Title
Metaplastic breast cancer: a comparison between the most common histologies with poor immunohistochemistry factors
Authors
Salim Abraham Barquet-Muñoz
Silvia Patricia Villarreal-Colin
Luis Alonso Herrera-Montalvo
Ernesto Soto-Reyes
Carlos Pérez-Plasencia
Jaime Coronel-Martínez
Delia Pérez-Montiel
Rafael Vázquez-Romo
David Cantú de León
Publication date
01-12-2015
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-015-1079-2

Other articles of this Issue 1/2015

BMC Cancer 1/2015 Go to the issue

Research article

Linear accelerator-based stereotactic radiosurgery in 140 brain metastases from malignant melanoma

Research article

Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival

Research article

Comparison of first-line chemotherapy based on irinotecan or other drugs to treat non-small cell lung cancer in stage IIIB/IV: a systematic review and meta-analysis

Research article

NKTR-102 Efficacy versus irinotecan in a mouse model of brain metastases of breast cancer

Research article

Long-term results of chemoradiotherapy for stage II-III thoracic esophageal cancer in a single institution after 2000 -with a focus on comparison of three protocols-

Research article

International trends in primary liver cancer incidence from 1973 to 2007
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits